285 related articles for article (PubMed ID: 16476710)
1. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.
Efthimiou P; Schwartzman S; Kagen LJ
Ann Rheum Dis; 2006 Sep; 65(9):1233-6. PubMed ID: 16476710
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup.
Schmidt J; Kermani TA; Bacani AK; Crowson CS; Matteson EL; Warrington KJ
Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1079-83. PubMed ID: 22328491
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as therapy for refractory polymyositis and dermatomyositis.
Noss EH; Hausner-Sypek DL; Weinblatt ME
J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up.
Molloy ES; Langford CA; Clark TM; Gota CE; Hoffman GS
Ann Rheum Dis; 2008 Nov; 67(11):1567-9. PubMed ID: 18677012
[TBL] [Abstract][Full Text] [Related]
5. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
Solau-Gervais E; Laxenaire N; Cortet B; Dubucquoi S; Duquesnoy B; Flipo RM
Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526
[TBL] [Abstract][Full Text] [Related]
6. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
7. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
8. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.
Fautrel B; Sibilia J; Mariette X; Combe B;
Ann Rheum Dis; 2005 Feb; 64(2):262-6. PubMed ID: 15184196
[TBL] [Abstract][Full Text] [Related]
9. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature.
Comarmond C; Plaisier E; Dahan K; Mirault T; Emmerich J; Amoura Z; Cacoub P; Saadoun D
Autoimmun Rev; 2012 Jul; 11(9):678-84. PubMed ID: 22155781
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
Strangfeld A; Hierse F; Kekow J; von Hinueber U; Tony HP; Dockhorn R; Listing J; Zink A
Ann Rheum Dis; 2009 Dec; 68(12):1856-62. PubMed ID: 19126559
[TBL] [Abstract][Full Text] [Related]
11. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.
Guignard S; Gossec L; Salliot C; Ruyssen-Witrand A; Luc M; Duclos M; Dougados M
Ann Rheum Dis; 2006 Dec; 65(12):1631-4. PubMed ID: 16901960
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic advances in myositis.
Aggarwal R; Oddis CV
Curr Opin Rheumatol; 2012 Nov; 24(6):635-41. PubMed ID: 22955021
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients.
Marie I; Menard JF; Hatron PY; Hachulla E; Mouthon L; Tiev K; Ducrotte P; Cherin P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1748-55. PubMed ID: 20722047
[TBL] [Abstract][Full Text] [Related]
18. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up.
Hengstman GJ; van den Hoogen FH; van Engelen BG
Eur Neurol; 2004; 52(1):61-3. PubMed ID: 15240986
[No Abstract] [Full Text] [Related]
19. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
20. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
